Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.

[1]  W. Talloen,et al.  Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. , 2019, Gastroenterology.

[2]  D. Hoffmann,et al.  Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. , 2019, ACS infectious diseases.

[3]  J. Pawlotsky,et al.  Chronic hepatitis B virus infection , 2018, The Lancet.

[4]  F. Zoulim,et al.  The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. , 2018, Antiviral research.

[5]  M. Yuen,et al.  Hepatitis B core protein as a therapeutic target , 2017, Expert opinion on therapeutic targets.

[6]  F. Pauwels,et al.  Antiviral profiling of the capsid assembly modulator BAY41‐4109 on full‐length HBV genotype A‐H clinical isolates and core site‐directed mutants in vitro , 2017, Antiviral research.

[7]  F. García-Alcalde,et al.  Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms , 2017, Scientific Reports.

[8]  N. Kootstra,et al.  Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. , 2016, The Journal of infectious diseases.

[9]  John F. Flaherty,et al.  Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. , 2015, Journal of hepatology.

[10]  J. Kao,et al.  Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance , 2014, Emerging Microbes & Infections.

[11]  A. Perelson,et al.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. , 2010, The Journal of infectious diseases.

[12]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[13]  M. Sherman,et al.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.